Atellica CH ECre_2

Enzymatic Creatinine ( Ecrea_2) Atellica CH - RGT 1400T

Registry build 21.09.26
4manufacturers in China registered for this device type
1catalogue number
2510(k) clearances naming this product code
16recalls on this code

Who Else Makes It

Concentrated in Zhejiang (1), Guangxi (1), Chongqing (1). 2 of them are registered as contract manufacturers, able to build to a buyer’s own specification.

Chinese manufacturers registered for FDA product code JFY
Manufacturer City Province Registered as Device types
Acon Biotech (Hangzhou) Co., Ltd. Hangzhou Zhejiang Contract manufacturer 29
Dongguan Honfield Precision Parts Co., Ltd. Zhangmutou, Dongguan Guangdong Contract manufacturer 8
Urit Medical Electronic Co., Ltd. Guilin Guangxi Contract manufacturer 28
Chong Qing Teco Huayi Pharm. Co. Shapingba Dist. Chongqing Contract manufacturer 18

Record

Regulatory record for Atellica CH ECre_2
Listed by Siemens Healthcare Diagnostics Inc, United States
FDA product code JFY
Device type Enzymatic Method, Creatinine
Device class Class 2
Regulation 21 CFR 862.1225
Establishment Contract manufacturer, Specification developer, Repacker / relabeller, Complaint-file establishment, Manufacturer, Exporter
510(k) K070727
Record published 2017-12-22
Record revised 2026-04-28 (version 9)

Specifications

Specifications
MRI safety Labeling does not contain MRI Safety Information
Label carries lot or batch number, expiry date
Storage Storage environment temperature 2 to 8 °C
Distribution end date 2026-04-27

Catalogue Numbers

Catalogue numbers for Atellica CH ECre_2
Catalogue number Size Status
11097533 Withdrawn

Same Product Code

Other products under the same FDA product code
Product Sold by Catalogue numbers
Creatinine Plus Roche Diagnostics Gmbh 3
Teco Diagnostics Teco Diagnostics 3
Pointe Scientific, Inc. Horiba Instruments Incorporated 3
Creatinine plus ver2 Roche Diagnostics Gmbh 3
Architect Abbott Laboratories 2
CR Cartridge LifeHealth, LLC 2
Alinity Abbott Laboratories 2
Creatinine LiquiColor® Stanbio Laboratory, L.P. 2
Pointe Scientific, Inc. Creatinine Enzymatic Horiba Instruments Incorporated 2
Automatic Urine Analyzer Urit Medical Electronic Co., Ltd. 2
Creatinine plus ver.2 Roche Diagnostics Gmbh 1
Dimension® Flex® reagent cartridge Ezcr Siemens Healthcare Diagnostics Inc 1

Showing 12 of 40. All products under Enzymatic Method, Creatinine

510(K) Clearances

FDA 510(k) clearances naming this product code
Clearance Decision date
K212223 2021-11-24
K090330 2009-05-22

Recalls Naming This Product

5 recalls name this product by its own identifiers, the 510(k) it is cleared under.

Recalls naming the identifiers of Atellica CH ECre_2
Recalled by Identified by Initiated FDA class Root cause Reason Quantity Closed
Siemens Healthcare Diagnostics Inc 510(k) number 2020-05-04 Class II Device Design The presence of N-acetyl-p-benzoquinone imine (NAPQI), a metabolite of acetaminophen, may cause interference in certain chemistry assays when testing patient samples. 1006 2021-09-20
Siemens Healthcare Diagnostics Inc 510(k) number 2020-05-04 Class II Device Design The presence of N-acetyl-p-benzoquinone imine (NAPQI), a metabolite of acetaminophen, may cause interference in certain chemistry assays when testing patient samples. 1488 2021-09-20
Siemens Healthcare Diagnostics Inc 510(k) number 2019-12-18 Class II Under Investigation by firm There is a potential for falsely depressed creatinine results for patients on phenindione therapy when using the enzymatic methodology. Interference has not been observed with the creatinine Jaffe methodology. 1,015 units 2020-06-25
Siemens Healthcare Diagnostics Inc 510(k) number 2019-12-18 Class II Under Investigation by firm There is a potential for falsely depressed creatinine results for patients on phenindione therapy when using the enzymatic methodology. Interference has not been observed with the creatinine Jaffe methodology. 824 units 2020-06-25
Siemens Healthcare Diagnostics Inc 510(k) number 2016-03-17 Class II Device Design Siemens Healthcare Diagnostics has become aware of N-Acetylcysteine (NAC) and Metamizole (Dipyrone) interference with Trinder and Trinder-like reaction assays. Siemens has confirmed that falsely depressed results may occur on samples drawn 137422 units total 2017-09-25

Recalls

7 of these are Class II. Class II means a temporary or reversible health consequence. Volume alone is not a quality signal: a manufacturer that ships more recalls more.

Recalls referencing this product code
Initiated FDA class Root cause Reason Quantity Closed
2020-05-04 Class II Device Design The presence of N-acetyl-p-benzoquinone imine (NAPQI), a metabolite of acetaminophen, may cause interference in certain chemistry assays when testing patient samples. 8261 2021-09-20
2020-05-04 Class II Device Design The presence of N-acetyl-p-benzoquinone imine (NAPQI), a metabolite of acetaminophen, may cause interference in certain chemistry assays when testing patient samples. 23,824 2021-09-20
2019-12-18 Class II Under Investigation by firm There is a potential for falsely depressed creatinine results for patients on phenindione therapy when using the enzymatic methodology. Interference has not been observed with the creatinine Jaffe methodology. 11,725 units 2020-06-25
2019-12-18 Class II Under Investigation by firm There is a potential for falsely depressed creatinine results for patients on phenindione therapy when using the enzymatic methodology. Interference has not been observed with the creatinine Jaffe methodology. 2,198 units 2020-06-25
2016-03-17 Class II Device Design Siemens Healthcare Diagnostics has become aware of N-Acetylcysteine (NAC) and Metamizole (Dipyrone) interference with Trinder and Trinder-like reaction assays. Siemens has confirmed that falsely depressed results may occur on samples drawn 137422 units total 2017-09-25
2016-03-17 Class II Device Design Siemens Healthcare Diagnostics has become aware of N-Acetylcysteine (NAC) and Metamizole (Dipyrone) interference with Trinder and Trinder-like reaction assays. Siemens has confirmed that falsely depressed results may occur on samples drawn 137422 units total 2017-09-25
2015-07-15 Class II Device Design Siemens has confirmed that the Dimension CREA and Dimension Vista CREA may produce falsely depressed results up to – 12.7% and -22% respectively, for a creatinine concentration of 1.5 mg/dL when hemolysis exceeds 200 mg/dL and 300 mg/dL res Total number Dimension Vista – 32,165, Dimension – 238,634 2017-03-24
2010-06-10 Not classified Device Design Results may be falsely depressed up to 0.4 mg/dL or falsely elevated up to 0.6 mg/dL across the assay range. 1,399 2013-12-19
2010-06-10 Not classified Device Design Patient results may be falsely depressed or falsely elevated across the assay range. 860 2013-03-19
2010-02-12 Not classified Nonconforming Material/Component The ECREA test results may be falsely elevated or depressed. 324 2010-10-13
2008-09-29 Not classified Component design/selection Reagent may exhibit unflagged inaccurate patient sample results. 12,773 cartons 2009-03-27

Source: U.S. FDA establishment registration and device listing records, public domain. Restructured for clarity and searchability. Not affiliated with or endorsed by the FDA. Records are records: nothing here is an offer of sale.

Where China Actually Supplies

Every device page names the company that lists it and the factories registered to make the same thing. These are the sections with the most of them.

5,100manufacturers registered in China
2,581device types they are registered for
340,248device records, each naming its maker
31provinces with a registered manufacturer